APA (7th ed.) Citation

Fragoso-Saavedra, S., Iruegas-Nunez, D. A., Quintero-Villegas, A., García-González, H. B., Nuñez, I., Carbajal-Morelos, S. L., . . . Valdés-Ferrer, S. I. (2020). A parallel-group, multicenter randomized, double-blinded, placebo-controlled, phase 2/3, clinical trial to test the efficacy of pyridostigmine bromide at low doses to reduce mortality or invasive mechanical ventilation in adults with severe SARS-CoV-2 infection: The Pyridostigmine In Severe COvid-19 (PISCO) trial protocol. BMC Infectious Diseases, 20(1), N.PAG. https://doi.org/10.1186/s12879-020-05485-7

Chicago Style (17th ed.) Citation

Fragoso-Saavedra, Sergio, et al. "A Parallel-group, Multicenter Randomized, Double-blinded, Placebo-controlled, Phase 2/3, Clinical Trial to Test the Efficacy of Pyridostigmine Bromide at Low Doses to Reduce Mortality or Invasive Mechanical Ventilation in Adults with Severe SARS-CoV-2 Infection: The Pyridostigmine In Severe COvid-19 (PISCO) Trial Protocol." BMC Infectious Diseases 20, no. 1 (2020): N.PAG. https://doi.org/10.1186/s12879-020-05485-7.

MLA (9th ed.) Citation

Fragoso-Saavedra, Sergio, et al. "A Parallel-group, Multicenter Randomized, Double-blinded, Placebo-controlled, Phase 2/3, Clinical Trial to Test the Efficacy of Pyridostigmine Bromide at Low Doses to Reduce Mortality or Invasive Mechanical Ventilation in Adults with Severe SARS-CoV-2 Infection: The Pyridostigmine In Severe COvid-19 (PISCO) Trial Protocol." BMC Infectious Diseases, vol. 20, no. 1, 2020, p. N.PAG, https://doi.org/10.1186/s12879-020-05485-7.